Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff
As Supernus' top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of marke...
Continue Reading →
